The slide to be stained for
CA125 comprised:
1. Appendix, 2. Salpinx, 3. Serous ovarian carcinoma grade II, 4.
Serous ovarian carcinoma grade III
All tissues were fixed in 10% neutral buffered formalin.
Criteria for assessing a CA125 staining as optimal included:
- A moderate to strong, predominantly
membranous staining reaction in virtually all the epithelial
cells of the salpinx.
- A moderate to strong distinct
predominantly membranous staining reaction in the majority of
the neoplastic cells in the two serous ovarian carcinomas.
- A weak to moderate staining of the
follicular dendritic network in the germinal centres of the
appendix.
- No staining reaction in the epithelial
cells of the appendix.
112 laboratories participated in this
assessment. 82 % achieved a sufficient mark. In table 1 the
antibodies (Abs) used and marks are summarized.
Table 1.
Abs and
assessment marks
for CA125, run 29
|
Concentrated Abs |
N |
Vendor |
Optimal |
Good |
Borderl. |
Poor |
Suff.1 |
Suff. OPS2 |
|
mAb3) clone
M11 |
39
1
1 |
Dako
Cisbio
NeoMarkers |
18 |
23 |
0 |
0 |
100 % |
100 % |
|
mAb clone
OV185:1 |
26
2
1
1
1
1
1
1 |
Novocastra/Leica
NeoMarkers
BioGenex
BioLogo
Euro-Diagnostica
Master Diagnostica
Monosan
Vector |
2 |
21 |
10 |
1 |
68 % |
83 % |
|
mAb clone
OC125 |
12
1
1
1 |
Dako
Cisbio
Immunologic
Signet Lab |
0 |
9 |
6 |
0 |
60 % |
- |
|
mAb clone
SPM111 |
1 |
NeoMarkers |
0 |
1 |
0 |
0 |
- |
- |
|
Ready-To-Use Abs |
|
|
|
|
|
|
|
|
mAb clone
OC125,
760-2610 |
11 |
Ventana |
0 |
8 |
3 |
0 |
73 % |
- |
mAb clone
OC125,
PM101 |
2 |
BioCare |
0 |
2 |
0 |
0 |
- |
- |
mAb clone
OC125,
325M-17 |
1 |
Cell Marque |
0 |
1 |
0 |
0 |
- |
- |
mAb clone M11,
IR701 |
4 |
Dako |
3 |
1 |
0 |
0 |
- |
- |
mAb clone
OV185:1,
PA0539 |
1 |
Novocastra/Leica |
0 |
1 |
0 |
0 |
- |
- |
mAb clone
OV185:1,
MS-1151-R7 |
1 |
NeoMarkers |
0 |
1 |
0 |
0 |
- |
- |
mAb clone SPM111,
ZM0019 |
1 |
Unknown |
0 |
1 |
0 |
0 |
- |
- |
|
Total |
112 |
|
23 |
69 |
19 |
1 |
- |
- |
|
Proportion |
|
|
20 % |
62 % |
17 % |
1 % |
82 % |
- |
1) Proportion of sufficient stains
(optimal or good), 2) Proportion of sufficient stains with optimal
protocol settings only, see below.
3) mAb: mouse monoclonal
antibody.
Following central protocol parameters were
used to obtain an optimal staining:
Concentrated Abs
mAb clone M11: The protocols giving an optimal result were
all based on
HIER with either
Tris-EDTA/EGTA pH 9 (2/7)*, Target Retrieval Solution pH 9 (EnVision
FLEX TRS high pH, Dako) (5/7), Target Retrieval Solution pH 6.1
(S1699, Dako) (2/3), Cell Conditioning 1 (BenchMark, Ventana)
(4/10), Bond Epitope Retrieval Solution 2 (Bond, Leica) (2/3) or
Citrate pH 6 (3/8) as the retrieval buffer. The mAb was typically
diluted in the range of 1:20– 1:2.000 depending on the total
sensitivity of the protocol employed. Using these protocol settings
all of 39 (100 %) laboratories produced a sufficient staining
(optimal or good).
* (number of optimal results/number of laboratories using this
buffer)
mAb clone OV185:1: The protocols giving an optimal result
were both based on HIER with
either Bond Epitope Retrieval Solution 2 (Bond, Leica) (1/3) or
EDTA/EGTA pH 8 (1/2) as the retrieval buffer. The mAb was diluted
1:5 - 1:100 depending on the total
sensitivity of the protocol employed. Using these protocol settings
5 out of 6 (83 %) laboratories produced a sufficient staining.
Ready-To-Use Abs
mAb clone M11 (prod. no IR701, Dako): The protocols giving an
optimal result were all based on HIER in PT-Link using Target
Retrieval Solution pH 9 (EnVision FLEX TRS high pH), an incubation
time of 20 min in the primary Ab and EnVision Flex (K8000) as the
detection system. Using these protocol settings all of 3 laboratories produced an
optimal staining.
- - -
The most frequent causes of insufficient staining were:
- Too low concentration of the primary Ab
- Omission of HIER
- Insufficient HIER - too short efficient HIER time and/or HIER in
citrate pH 6.0
- Endogenous biotin
In this assessment and in concordance with the previous assessment (run
15, 2005) the prevalent feature of an insufficient staining was a
generally too weak or completely false negative staining reaction of
the cells expected to stain. This was observed in all the 20 stains,
which in this run was assessed as insufficient. In 4 of the insufficient cases (20%) also
a false positive staining due to endogenous biotin was observed. The
weak or false negative staining was seen in both the epithelial
cells of the salpinx and in the two serous ovarian carcinomas, whereas
the false positive reaction of endogenous biotin was seen in the
epithelial cells of the appendix.
The mAb clone M11, both as a concentrate and as a
Ready-To-Use (RTU) format, gave a higher pass rate (100 %) and a
higher proportion of optimal results than the other Abs (see Table
1), indicating that clone M11 is robust and applicable in all the IHC
staining platforms and HIER settings used by the laboratories.
In comparison, the pass rate for the mAb clone OC125 with similar IHC staining platforms and HIER settings was
markedly lower (69 %) and no optimal
result obtained. However, mAb clone M11 from Dako and NeoMarkers is produced as an
ascites format, which may cause a false positive
MAG staining in
tissues of blood type A (no data could be found on the Ab format
from Cisbio).
The mAb clone OC125 from Dako, Cell Marque and
Ventana is also produced as an ascites format (no data could be
found on the Ab format from BioCare).
The mAb clone OV185:1 from
e.g. Novocastra and NeoMarkers was the only Ab provided as a
supernatant (thus without the
potential MAG reaction) and giving an optimal
staining result.
In accordance with the previous assessment of CA125, salpinx was
found to be a reliable positive control: All laboratories obtaining
a moderate to strong distinct membranous staining of virtually all
the epithelial cells were assessed as sufficient. In the optimal
stains also a
weak to moderate staining reaction was seen in the follicular dendritic
network of the germinal centres in the appendix.
This was the 2nd assessment of CA125 in NordiQC. The proportion of sufficient results
increased from 67 % in run 15, 2005, to 82 % in the current run
(table 2). The
higher pass rate may in part be due to the increased use of the mAb clone M11
(6/48 = 13% in run 15, 41/112 = 37% in the current run).
Table 2:
Proportion of sufficient results for CA125 in the two NordiQC runs
performed
| |
Run 15 2005 |
Run 29 2010 |
|
Participants, n= |
48 |
112 |
|
Sufficient results |
67 % |
82 % |
Conclusion
The mAb clones M11 and OV185:1 are both recommendable Abs for
CA125. However clone M11 is typically sold as ascites format, hence caution
must be taken with tissue from patients with blood group A. HIER is mandatory for
optimal performance. Normal salpinx is a recommendable positive
control: Virtually all the epithelial cells must show a moderate to
strong, distinct membranous staining. |